Cargando…
Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia
This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou Un...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055912/ https://www.ncbi.nlm.nih.gov/pubmed/33875780 http://dx.doi.org/10.1038/s41598-021-88080-3 |
_version_ | 1783680539443593216 |
---|---|
author | Zhang, Binglei Chen, Lingyun Zhou, Jian Zu, Yingling Gui, Ruirui Li, Zhen Wang, Juan Yu, Fengkuan Zhang, Yanli Zhao, Huifang Ji, Zhenyu Song, Yongping |
author_facet | Zhang, Binglei Chen, Lingyun Zhou, Jian Zu, Yingling Gui, Ruirui Li, Zhen Wang, Juan Yu, Fengkuan Zhang, Yanli Zhao, Huifang Ji, Zhenyu Song, Yongping |
author_sort | Zhang, Binglei |
collection | PubMed |
description | This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou University from July 2017 to October 2019. They were divided into control(16 patients) and ruxolitinib (41 patients) groups. For aGVHD prophylaxis, the control group received post-transplantation cyclophosphamide, antithymocyte globulin-Fresenius, cyclosporine A, and mycophenolate mofetil, while in the ruxolitinib group, ruxolitinib 5 mg/d in adults or 0.07–0.1 mg/(kg d) in children was administered from the day of neutrophil engraftment to 100 days post-transplantation based on control group. We found 55 patients had successful reconstitution of hematopoiesis; No significant difference was found in cGVHD, hemorrhagic cystitis, pulmonary infection, intestinal infection, Epstein-Barr virus infection, cytomegalovirus infection, relapse, death, and nonrelapse mortality. The incidences of aGVHD (50 vs. 22%, P = 0.046) and grade II–IV aGVHD (42.9 vs. 12.2%, P = 0.013) were significantly higher in the control group than in the ruxolitinib group. No significant differences were observed in overall survival (P = 0.514), disease-free survival (P = 0.691), and cumulative platelet transfusion within 100 days post-transplantation between two groups. This suggests early application of ruxolitinib can reduce the incidence and severity of aGVHD and patients are well tolerated. |
format | Online Article Text |
id | pubmed-8055912 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-80559122021-04-22 Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia Zhang, Binglei Chen, Lingyun Zhou, Jian Zu, Yingling Gui, Ruirui Li, Zhen Wang, Juan Yu, Fengkuan Zhang, Yanli Zhao, Huifang Ji, Zhenyu Song, Yongping Sci Rep Article This study aimed to observe the safety and clinical efficacy of early application of ruxolitinib to prevent acute graft-versus-host disease (aGVHD) after alternative donor transplantation in acute leukemia. There were 57 patients undergoing allo-HSCT at the Affiliated Cancer Hospital of Zhengzhou University from July 2017 to October 2019. They were divided into control(16 patients) and ruxolitinib (41 patients) groups. For aGVHD prophylaxis, the control group received post-transplantation cyclophosphamide, antithymocyte globulin-Fresenius, cyclosporine A, and mycophenolate mofetil, while in the ruxolitinib group, ruxolitinib 5 mg/d in adults or 0.07–0.1 mg/(kg d) in children was administered from the day of neutrophil engraftment to 100 days post-transplantation based on control group. We found 55 patients had successful reconstitution of hematopoiesis; No significant difference was found in cGVHD, hemorrhagic cystitis, pulmonary infection, intestinal infection, Epstein-Barr virus infection, cytomegalovirus infection, relapse, death, and nonrelapse mortality. The incidences of aGVHD (50 vs. 22%, P = 0.046) and grade II–IV aGVHD (42.9 vs. 12.2%, P = 0.013) were significantly higher in the control group than in the ruxolitinib group. No significant differences were observed in overall survival (P = 0.514), disease-free survival (P = 0.691), and cumulative platelet transfusion within 100 days post-transplantation between two groups. This suggests early application of ruxolitinib can reduce the incidence and severity of aGVHD and patients are well tolerated. Nature Publishing Group UK 2021-04-19 /pmc/articles/PMC8055912/ /pubmed/33875780 http://dx.doi.org/10.1038/s41598-021-88080-3 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zhang, Binglei Chen, Lingyun Zhou, Jian Zu, Yingling Gui, Ruirui Li, Zhen Wang, Juan Yu, Fengkuan Zhang, Yanli Zhao, Huifang Ji, Zhenyu Song, Yongping Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title | Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title_full | Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title_fullStr | Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title_full_unstemmed | Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title_short | Ruxolitinib early administration reduces acute GVHD after alternative donor hematopoietic stem cell transplantation in acute leukemia |
title_sort | ruxolitinib early administration reduces acute gvhd after alternative donor hematopoietic stem cell transplantation in acute leukemia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8055912/ https://www.ncbi.nlm.nih.gov/pubmed/33875780 http://dx.doi.org/10.1038/s41598-021-88080-3 |
work_keys_str_mv | AT zhangbinglei ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT chenlingyun ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT zhoujian ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT zuyingling ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT guiruirui ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT lizhen ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT wangjuan ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT yufengkuan ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT zhangyanli ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT zhaohuifang ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT jizhenyu ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia AT songyongping ruxolitinibearlyadministrationreducesacutegvhdafteralternativedonorhematopoieticstemcelltransplantationinacuteleukemia |